Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Inclusion Criteria: * Histologic diagnosis of multiple myeloma; * Age:18-80 years; * Eastern Cooperative Oncology Group (ECOG) status 0-3, * Estimated survival time \> 3 months; * Acceptable liver function (bilirubin\<2.5×ULN, Alanine transaminase (ALT) or Aspartate Aminotransferase (AST)\<2.5×ULN), * No history of other malignancies; * No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation; * No other serious diseases which conflict with the treatment in the present trial; * No concurrent treatments that conflict with the treatments in the present trial; * Voluntary participation and signed the informed consent. Exclusion Criteria: * The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication; * The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies; * The patients with neuropathy; * The patients with mentally ill / unable to obtain informed consent; * The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results; * The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects; * The patients with a history of allergy to test drug; * The patients not suitable to participate in the investigator judged by researchers.